Citations

Clear

86 citation(s) found for "Smith, David".

Skp2 inhibits FOXO1 in tumor suppression through ubiquitin-mediated degradation
Regan, Kevin M., Wang, Diping, Smith, David I, Deursen, Jan M. A. van, Tindall, Donald J., Huang, Haojie , Wang, Fang , Smith, David I

Mayo Clinic

Proceedings of the National Academy of Sciences | January 24, 2005 | Volume: 102 | Issue: 5 | Pages: 1649-1654

10.1073/pnas.0406789102 | PMID 15668399 Get It

Forkhead transcription factors FOXO1 (FKHR), FOXO3a (FKHRL1), and FOXO4 (AFX) play a pivotal role in tumor suppression by inducing growth arrest and apoptosis. Loss of function of these factors due to phosphorylation and proteasomal degradation has been implicated in cell transformation and malignancy. However, the ubiquitin ligase necessary for the ubiquitination of the FOXO factors and the relevance of this regulation to tumorigenesis have not been characterized. Here we demonstrate that Skp2, an oncogenic subunit of the Skp1/Cul1/F-box protein ubiquitin complex, interacts with, ubiquitinates, and promotes the degradation of FOXO1. This effect of Skp2 requires Akt-specific phosphorylation of FOXO1 at Ser-256. Moreover, expression of Skp2 inhibits transactivation of FOXO1 and abolishes the inhibitory effect of FOXO1 on cell proliferation and survival. Furthermore, expression of the FOXO1 protein is lost in a mouse lymphoma model, where Skp2 is overexpressed. These data suggest that the Skp2-promoted proteolysis of FOXO1 plays a key role in tumorigenesis.
Malignant pheochromocytoma: current status and initiatives for future progress
Eisenhofer, Graeme , Bornstein, Stefan R. , Brouwers, Frederieke M., Cheung, Nai‐Kong V. , Giordano, Thomas J. , Lehnert, Hendrik, Manger, William M., Neumann, Hartmut P.H., Pacák, Karel , Shulkin, Barry L. , Smith, David I, Tischler, Arthur S. , Dahia, Patricia L. M. , Krijger, Ronald R. de , Greene, Lloyd A. , Goldstein, David S. , Maris, John M. , Smith, David I, Young, William F. , Shulkin, Barry L

Mayo Clinic

Endocrine-Related Cancer | December 2, 2004 | Volume: 11 | Issue: 3 | Pages: 423-436

10.1677/erc.1.00829 | PMID 15369446 Get It

Abstract Pheochromocytomas are rare catecholamine-producing neuroendocrine tumors that are usually benign, but which may also present as or develop into a malignancy. Predicting such behavior is notoriously difficult and there are currently no curative treatments for malignant tumors. This report follows from a workshop at the Banbury Conference Center, Cold Spring Harbor, New York, on the 16th–18th November 2003, held to review the state of science and to facilitate future progress in the diagnosis and treatment of malignant pheochromocytoma. The rarity of the tumor and the resulting fragmented nature of studies, typically involving small numbers of patients, represent limiting factors to the development of effective treatments and diagnostic or prognostic markers for malignant disease. Such development is being facilitated by the availability of new genomics-based tools, but for such approaches to succeed ultimately requires comprehensive clinical studies involving large numbers of patients, stringently collected clinical data and tumor samples, and interdisciplinary collaborations among multiple specialist centers. Nevertheless, the well-characterized hereditary basis and the unique functional nature of these neuroendocrine tumors provide a useful framework that offers advantages for establishing the pathways of tumorigenesis and malignancy. Such findings may have relevance for understanding the basis of other more common malignancies where similar frameworks are not available. As the relevant pathways leading to pheochromocytoma are established it should be possible to take advantage of the new generation of drugs being developed to target specific pathways in other malignancies. Again the success of this will require well-designed and coordinated multicenter studies.
The Heat Shock Protein 70 Cochaperone Hip Enhances Functional Maturation of Glucocorticoid Receptor
Nelson, Gregory M. , Prapapanich, Viravan, Carrigan, Patricia E., Roberts, Patricia J., Smith, David F. , Riggs, Daniel L.

Mayo Clinic

Molecular Endocrinology | April 13, 2004 | Volume: 18 | Issue: 7 | Pages: 1620-1630

10.1210/me.2004-0054 | PMID 15071092 Get It

Structure of the large FK506-binding protein FKBP51, an Hsp90-binding protein and a component of steroid receptor complexes
Sinars, Cindy R., Cheung‐Flynn, Joyce , Rimerman, Ronald A., Scammell, Jonathan G. , Smith, David F. , Clardy, Jon

Mayo Clinic

Proceedings of the National Academy of Sciences | February 4, 2003 | Volume: 100 | Issue: 3 | Pages: 868-873

10.1073/pnas.0231020100 | PMID 12538866 Get It

The ability to bind immunosuppressive drugs such as cyclosporin and FK506 defines the immunophilin family of proteins, and the FK506-binding proteins form the FKBP subfamily of immunophilins. Some FKBPs, notably FKBP12 (the 12-kDa FK506-binding protein), have defined roles in regulating ion channels or cell signaling, and well established structures. Other FKBPs, especially the larger ones, participate in important biological processes, but their exact roles and the structural bases for these roles are poorly defined. FKBP51 (the 51-kDa FKBP) associates with heat shock protein 90 (Hsp90) and appears in functionally mature steroid receptor complexes. In New World monkeys, FKBP51 has been implicated in cortisol resistance. We report here the x-ray structures of human FKBP51, to 2.7 Å, and squirrel monkey FKBP51, to 2.8 Å, by using multiwavelength anomalous dispersion phasing. FKBP51 is composed of three domains: two consecutive FKBP domains and a three-unit repeat of the TPR (tetratricopeptide repeat) domain. This structure of a multi-FKBP domain protein clarifies the arrangement of these domains and their possible interactions with other proteins. The two FKBP domains differ by an insertion in the second that affects the formation of the progesterone receptor complex.
Overexpression of FKBP51 in idiopathic myelofibrosis regulates the growth factor independence of megakaryocyte progenitors
Giraudier, Stéphane , Chagraoui, Hédia, Komura, Emiko, Barnache, Stéphane, LeCouédic, Jean Pierre, Larbret, Frédéric, Taksin, Anne‐Laure, Moreau-Gachelin, Françoise, Casadevall, Nicole, Tulliez, Michel, Hulin, Anne , Debili, Najet, Vainchenker, William , Blanchet, Benoı̂t , Smith, David F.

Mayo Clinic

Blood | September 26, 2002 | Volume: 100 | Issue: 8 | Pages: 2932-2940

10.1182/blood-2002-02-0485 | PMID 12351405 Get It

Idiopathic myelofibrosis (IMF) is a chronic myeloproliferative disorder characterized by megakaryocyte hyperplasia and bone marrow fibrosis. Biologically, an autonomous megakaryocyte growth and differentiation is noticed, which contributes to the megakaryocyte accumulation. To better understand the molecular mechanisms involved in this spontaneous growth, we searched for genes differentially expressed between normal megakaryocytes requiring cytokines to grow and IMF spontaneously proliferating megakaryocytes. Using a differential display technique, we found that the immunophilin FKBP51 was 2 to 8 times overexpressed in megakaryocytes derived from patients' CD34+ cells in comparison to normal megakaryocytes. Overexpression was moderate and confirmed in 8 of 10 patients, both at the mRNA and protein levels. Overexpression of FKBP51 in a UT-7/Mpl cell line and in normal CD34+ cells induced a resistance to apoptosis mediated by cytokine deprivation with no effect on proliferation. FKBP51 interacts with both calcineurin and heat shock protein (HSP)70/HSP90. However, a mutant FKBP51 deleted in the HSP70/HSP90 binding site kept the antiapoptotic effect, suggesting that the calcineurin pathway was responsible for the FKBP51 effect. Overexpression of FKBP51 in UT-7/Mpl cells induced a marked inhibition of calcineurin activity. Pharmacologic inhibition of calcineurin by cyclosporin A mimicked the effect of FKBP51. The data support the conclusion that FKBP51 inhibits apoptosis through a calcineurin-dependent pathway. In conclusion, FKBP51 is overexpressed in IMF megakaryocytes and this overexpression could be, in part, responsible for the megakaryocytic accumulation observed in this disorder by regulating their apoptotic program.
Discovery of 1,5-Benzodiazepines with Peripheral Cholecystokinin (CCK-A) Receptor Agonist Activity. 1. Optimization of the Agonist “Trigger”
Aquino, Christopher, Armour, Duncan, Berman, Judd, Birkemo, Larry S., Carr, Robin A. E., Croom, Dallas K., Dezube, Milana, Dougherty, R. W., Ervin, Gregory N., Grizzle, Mary K., Head, Julie E., Hirst, Gavin C. , James, Michael K. , Johnson, Michael F., Queen, Kennedy L., Rimele, Thomas J., Smith, David Norman , Sugg, Elizabeth E., Miller, Laurence J.

Mayo Clinic

Journal of Medicinal Chemistry | July 26, 2002 | Volume: 39 | Issue: 2 | Pages: 562-569

10.1021/jm950626d | PMID 8558528 Get It